Quick Summary
- Shares of Definium Therapeutics (DFTX) surged approximately 20% following successful Phase 3 Panorama trial results for DT120 ODT in treating generalized anxiety disorder.
- Participants receiving DT120 ODT 100Āµg experienced a 9.8-point reduction in HAM-A scores compared to a 4.7-point decrease in the placebo group by Week 12.
- DT120 ODT has now achieved positive outcomes in three Phase 3 trials, including two studies focused on anxiety and one on depression.
- The drug demonstrated strong tolerability, with discontinuation rates virtually matching between active treatment and placebo groups (10.4% versus 10.3%).
- The company anticipates submitting a New Drug Application to the FDA during the first half of 2027, with a pre-submission meeting set for Q4 2026.
Definium Therapeutics (DFTX) shares climbed nearly 20% during premarket hours on Monday following the biotechnology company’s announcement of encouraging topline data from the Phase 3 Panorama trial evaluating DT120 ODT, an LSD-derived candidate for generalized anxiety disorder (GAD).
The biotech’s shares have experienced remarkable growth this year, nearly tripling as regulatory bodies and investors show increasing enthusiasm for psychedelic-derived therapeutic approaches.
The Panorama trial successfully achieved both its primary endpoint and all key secondary efficacy measures. Participants who received a single 100-microgram dose of DT120 ODT experienced a 9.8-point reduction on the Hamilton Anxiety Rating Scale (HAM-A) over 12 weeks, compared to only a 4.7-point decline in the control group.
The treatment’s advantage over placebo measured 5.1 points, corresponding to an effect size of 0.64.
Particularly notable was the rapid onset of therapeutic benefit. Measurable differences in efficacy emerged as early as the second day following administration and persisted consistently throughout the entire study duration.
Third Consecutive Positive Phase 3 Outcome
The Panorama study represents the third successful Phase 3 trial for DT120 ODT. Previously, the company reported positive results from the Voyage study in GAD last August, followed by encouraging data from the Emerge study in major depressive disorder announced in June.
Chief Executive Officer Robert Barrow emphasized that securing two successful GAD trials strengthens the company’s ability to demonstrate the drug’s genuine therapeutic mechanism to regulatory authorities. He highlighted that approximately a dozen development programs have unsuccessfully attempted to gain FDA approval for GAD treatments during the past two decades.
Generalized anxiety disorder impacts approximately 26 million adults in the United States and is commonly treated through a combination of antidepressant medications, anxiolytics, and therapeutic counseling.
The 245-participant Panorama study incorporated a 50-microgram dose cohort designed to mitigate functional unblinding risks, where participants might deduce their treatment assignment based on the medication’s characteristic effects. Despite this design feature, participants receiving either dose level could accurately identify when they received active treatment versus placebo.
The 100-microgram dose demonstrated superior therapeutic benefit compared to the 50-microgram arm, which Barrow indicated would facilitate regulatory discussions.
Safety Profile and Regulatory Submission Plans
The safety data aligned with findings from previous clinical studies. The majority of treatment-related adverse events were classified as mild to moderate in severity, temporary in nature, and predominantly concentrated on the dosing day.
Participant discontinuation rates showed remarkable similarity: 10.4% in the DT120 ODT arm compared to 10.3% in the placebo group.
Across more than 1,000 treatment sessions conducted within the Phase 3 program through September 10, 2026, an impressive 97% of participants satisfied end-of-session discharge criteria within eight hours.
Definium has secured a pre-NDA consultation with the FDA scheduled for the fourth quarter of 2026 and plans to file a complete New Drug Application during the first half of 2027.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
